XenoPort names new senior vice president and CMO

Dr Stamler brings to XenoPort over 15 years of clinical development experience, most recently serving as the chief scientific officer and head of drug development for Prestwick Pharmaceuticals.

Prior to Prestwick, Dr Stamler was employed by Fujisawa Pharmaceutical Company. Dr Stamler received his BA and MD degrees from the University of Chicago.

Ronald Barrett, CEO of XenoPort, said: “David’s broad experience and expertise in central nervous system drug development at small and large biopharmaceutical companies will be of tremendous value as we advance our pipeline of product candidates.”